1 / 5

Methods

keefer
Télécharger la présentation

Methods

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The HORIZONS AMI trialDariusz Dudek, Krzyszto Zmudka, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Bruce R. Brodie, Ran Kornowski, Franz Hartmann, Martin Mockel, Andrzej Ochala, Helen Parise, Roxana Mehran, Gregg W. Stone

  2. Methods • A total of 3602 patients at 123 centers in 11 countries with AMI undergoing primary PCI were randomized tobivalirudin monotherapy or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors. • Outcomes were analyzed according to age above or below the median of 60.2 years: • Bivalirudin (n=1800) • age ≤60.2 years (n=923) • age >60.2 years (n=877) • UFH+GPI (n=1802) • age ≤60.2 years (n=885) • age >60.2 years (n=917) Dudek et al ACC 2008

  3. Outcomes, Age ≤ 60.2 years P=0.168 P=0.0012* P=0.354 P=0.109 *P<0.05 Dudek et al ACC 2008

  4. Outcomes, Age > 60.2 years P=0.156 P=0.013* P=0.512 P=0.033* *P<0.05 Dudek et al ACC 2008

  5. Conclusions • In patients with AMI undergoing primary PCI, bivalirudin monotherapy significantly reduces major bleeding and net adverse clinical events, effects which are independent of age. Dudek et al ACC 2008

More Related